Treatment of Multiple Sclerosis in Primary-Progressive MS

This protocol applies to patients with primary-progressive multiple sclerosis (PPMS) — a specific subtype of MS requiring a dedicated treatment approach distinct from other MS forms.

Clinical Scenario

The patient has primary-progressive multiple sclerosis. This subtype drives the selection of a specific treatment strategy, as outlined in the full protocol.

Treatment Approach

For patients with primary-progressive MS, treatment may include ocrelizumab. The complete structured regimen — full sequencing, administration details, and monitoring guidance — is available in the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/1352458517751049

Consider treatment with ocrelizumab for patients with primary-progressive MS.

View source ↗